| Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 20211295 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Despite the widespread use of pharmacological and/or interventional reperfusion therapies, recovery of cardiac function in myocardial infarction (MI) patients is often modest or even absent. Unlike classical pharmacological treatments, the use of progenitor cells could potentially restore functional tissue in regions that otherwise would form only scar. However, a major limitation of autologous cell therapy is the deleterious influence of age and cardiac risk factors on progenitor cell activity. TRIAL DESIGN: The ENACT-AMI trial is a phase IIb, double-blind, randomized placebo-controlled trial, using transplantation of autologous early endothelial progenitor cells (EPCs) for patients who have suffered large MI. Circulating mononuclear cells (MNCs) are obtained by apheresis and subjected to differential culture for 3 days to select a population of highly regenerative, endothelial-like, culture modified MNCs (E-CMMs), often referred to as "early EPCs." A total of 99 patients will be randomized to placebo (Plasma-Lyte A), autologous E-CMMs, or E-CMMs transfected with human endothelial nitric oxide synthase delivered by coronary injection into the infarct-related artery. The primary efficacy end point is change from baseline to 6 months in global left ventricular ejection fraction by cardiac MRI; secondary endpoints include regional wall motion, wall thickening, infarct volume, time to clinical worsening, and quality of life. CONCLUSIONS: This will be the first clinical trial to include a strategy designed to enhance the function of autologous progenitor cells by overexpressing endothelial nitric oxide synthase, and the first to use combination gene and cell therapy for the treatment of cardiac disease. |
| | |
Authors:
|
Monica Taljaard; Michael R Ward; Michael J B Kutryk; David W Courtman; Nancy J Camack; Shaun G Goodman; Thomas G Parker; Alexander J Dick; Jacques Galipeau; Duncan J Stewart |
Related Documents
:
|
20153355 - Multistability property in cardiac ionic models of mammalian and human ventricular cells. 19649225 - Structural remodelling in heart failure. 7586355 - Reduced contraction and altered frequency response of isolated ventricular myocytes fro... 10355875 - Expression of extracellular matrix components fibronectin and laminin in the human feta... 12360125 - Impact of revascularization and myocardial viability determined by nitrate-enhanced tc-... 11352325 - Is atherosclerosis an infectious disease? |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: American heart journal Volume: 159 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-09 Completed Date: 2010-04-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 354-60 Citation Subset: AIM; IM |
Affiliation:
|
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada. mtaljaard@ohri.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Double-Blind Method Humans Myocardial Infarction / surgery* Nitric Oxide Synthase Type III / genetics, metabolism* Research Design* Stem Cell Transplantation* Stem Cells / enzymology* Transfection Transplantation, Autologous Up-Regulation |
| Chemical | |
Reg. No./Substance:
|
EC 1.14.13.39/Nitric Oxide Synthase Type III |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial f...
Next Document: Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-A randomized,...